Michael Kauffman, Chief Executive Officer at Karyopharm Therapeutics Inc. (KPTI), sold 27,932 shares at $22.38 ($623K) on 2020-03-09, disclosed to the SEC on 2020-03-11.
Open-market sale of $623k KPTI by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $22.38 | 3,000 | $67K | 10.8% |
| 2 | $22.58 | 7,000 | $158K | 25.4% |
| 3 | $22.11 | 7,932 | $175K | 28.2% |
| 4 | $22.11 | 7,932 | $175K | 28.2% |
| 5 | $22.64 | 2,068 | $47K | 7.5% |
| Total | $22.30 avg | 27,932 |
| $623K |
| 100% |
| Filing → |
| KPTI | SELL | 2022-03-02 | $128K | — | Filing → |
| KPTI | SELL | 2022-02-22 | $440K | — | Filing → |
| KPTI | SELL | 2022-02-09 | $266K | — | Filing → |